Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome

Contraception
Roberto UrasA M Paoletti

Abstract

Chlormadinone acetate (CMA) is a progestin compound similar to progesterone, with antiandrogenic properties. In healthy eumenorrheic women, it was demonstrated that the monophasic estroprogestin formulation containing CMA (2 mg) plus ethinyl estradiol (EE) (30 mcg) (EE30+CMA) is efficacious both in reducing hyperandrogenic symptoms, fat mass and in improving lipoprotein panel, without changes in insulin-glucose metabolism. These metabolic properties are important for women affected by polycystic ovary syndrome (PCOS) in whom there is a predisposition to insulin resistance. We studied whether in young nonobese women with PCOS (15 subjects, EE30+CMA-PCOS group) a six-cycle treatment with EE30+CMA can reduce androgen levels, androgen bioavailability and the score of hirsutism and acne, and modify glucose-insulin metabolism evaluated by the oral glucose tolerance test and the body composition evaluated by bio-impedenziometry. These parameters were evaluated before (first visit) and during the sixth cycle of EE30+CMA (second visit). All the results were compared with those of a matched-age-group of nonobese PCOS women (15 subjects, no OC-PCOS group) evaluated before (first visit) and after six menstrual cycles in which they did not ...Continue Reading

References

Dec 1, 1991·The Journal of Clinical Investigation·J SvedbergP Björntorp
Mar 1, 1990·The Journal of Clinical Endocrinology and Metabolism·A DunaifA Dobrjansky
May 28, 1993·Annals of the New York Academy of Sciences·I M Golland, M E Elstein
Feb 13, 2001·QJM : Monthly Journal of the Association of Physicians·V L ArmstrongP M Bell
Feb 8, 2003·Molecular and Cellular Endocrinology·Béatrice TérouanneCharles Sultan
Feb 26, 2003·Drugs·Daniel Raudrant, Thomas Rabe
Nov 1, 1961·The Journal of Clinical Endocrinology and Metabolism·D FERRIMAN, J D GALLWEY
Dec 13, 2003·Maturitas·Adolf E SchindlerJos H H Thijssen
Nov 24, 2004·Clinical Nutrition : Official Journal of the European Society of Parenteral and Enteral Nutrition·Ursula G KyleUNKNOWN ESPEN
Mar 26, 2005·Human Reproduction Update·J Vrbíková, D Cibula
Jun 10, 2005·Clinical Endocrinology·Ashim KumarRicardo Azziz
Dec 17, 2005·The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception·P Bouchard
May 13, 2009·Maturitas·Regine Sitruk-Ware

❮ Previous
Next ❯

Citations

Sep 16, 2011·American Journal of Clinical Dermatology·Mercedes Gómez VázquezMaria D Iniesta
Sep 26, 2014·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Nicolas MendozaAlessandro D Genazzani
Jun 12, 2014·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Giovanni GrandiAngelo Cagnacci
May 23, 2015·Expert Opinion on Pharmacotherapy·Morena Luigia RoccaMichele Morelli
Dec 9, 2017·Reproductive Biology and Endocrinology : RB&E·Sebastião Freitas de Medeiros
Mar 18, 2015·Hormone Molecular Biology and Clinical Investigation·Susan Sam
Dec 7, 2017·The Journal of Clinical Endocrinology and Metabolism·Costanzo MorettiAndrea Lenzi
Apr 26, 2011·Current Opinion in Allergy and Clinical Immunology

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.